Home › Companies › Ionis Pharmaceuticals, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Ionis Pharmaceuticals, Inc.’s Form 8-K, filed June 8, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 4, 2026: 6 items on Ionis Pharmaceuticals, Inc.’s Form 8-K, filed June 8, 2026: 4 approved · 2 passed (calculated).
Notable dissent: 1 director (14.8% against); 1 other board item (23.0% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Ionis Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Ionis Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 8, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Spencer R. Berthelsen | 119,824,353 | 20,816,547 | 98,115 | -- | 12,305,695 | 85% | Passed (calculated) | — |
| Elect Director: Joan E. Herman | 135,599,646 | 5,076,895 | 62,474 | -- | 12,305,695 | 96% | Passed (calculated) | — |
| 2. Advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of the named executive officers, as disclosed | 135,537,973 | 5,088,105 | 112,937 | -- | 12,305,695 | 96% | Approved | — |
| 3. Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc | 108,377,084 | 32,303,288 | 58,643 | -- | 12,305,695 | 77% | Approved | — |
| 4. Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the termination date of the plan | 140,348,001 | 332,204 | 58,810 | -- | 12,305,695 | 99.8% | Approved | — |
| 5. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year | 148,893,646 | 4,000,539 | 150,525 | -- | 0 | 97% | Approved | — |
Source: Ionis Pharmaceuticals, Inc., Form 8-K, filed with the SEC on June 8, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
484 asset managers disclosed a vote on at least one Ionis Pharmaceuticals, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Joan E. Herman
Ionis Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Joan E. Herman”): 135,599,646 for, 5,076,895 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 117 asset managers below reported 81,013,475 for, 2,283,538 against, 1,764 abstained, 160 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,414,463 | 14 | 0 | 0 | For |
| Fidelity | 17,072,170 | 0 | 0 | 0 | For |
| Capital Group | 15,689,002 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,173,586 | 2,132,721 | 0 | 0 | Mixed |
| NEW ECONOMY FUND | 4,723,802 | 0 | 0 | 0 | For |
| BlackRock | 3,679,155 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 1,963,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,536,094 | 0 | 0 | 0 | For |
| State Street | 1,308,413 | 0 | 0 | 0 | For |
| JPMorgan | 1,296,917 | 0 | 0 | 0 | For |
| American Century | 1,275,849 | 0 | 0 | 0 | For |
| Jackson National | 982,760 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 800,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 598,636 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 594,587 | 0 | 0 | 0 | For |
| MFS | 573,889 | 0 | 0 | 0 | For |
| Invesco | 546,518 | 0 | 0 | 0 | For |
| TIAA | 459,061 | 0 | 0 | 0 | For |
| First Trust | 411,205 | 0 | 0 | 0 | For |
| Neuberger Berman | 350,745 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 347,272 | 0 | 0 | 0 | For |
| Goldman Sachs | 341,791 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 333,637 | 0 | 0 | 0 | For |
| ARK ETF Trust | 269,786 | 0 | 0 | 0 | For |
| MassMutual | 258,430 | 0 | 0 | 0 | For |
Showing the 25 largest of 117 asset managers. All 117 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
85% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Spencer R. Berthelsen
Ionis Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Spencer R. Berthelsen”): 119,824,353 for, 20,816,547 against, per its Form 8-K filed June 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 117 asset managers below reported 74,662,984 for, 8,634,029 against, 1,764 abstained, 160 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,403,967 | 10,510 | 0 | 0 | For |
| Fidelity | 17,072,170 | 0 | 0 | 0 | For |
| Capital Group | 15,689,002 | 0 | 0 | 0 | For |
| T. Rowe Price | 0 | 5,306,307 | 0 | 0 | Against |
| NEW ECONOMY FUND | 4,723,802 | 0 | 0 | 0 | For |
| BlackRock | 3,679,155 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 1,963,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,536,094 | 0 | 0 | 0 | For |
| State Street | 4,038 | 1,304,375 | 0 | 0 | Against |
| JPMorgan | 1,296,917 | 0 | 0 | 0 | For |
| American Century | 1,275,849 | 0 | 0 | 0 | For |
| Jackson National | 490,004 | 492,756 | 0 | 0 | Mixed |
| Franklin Custodian Funds | 800,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 0 | 598,636 | 0 | 0 | Against |
| MUTUAL FUND SERIES TRUST | 594,587 | 0 | 0 | 0 | For |
| MFS | 573,889 | 0 | 0 | 0 | For |
| Invesco | 546,518 | 0 | 0 | 0 | For |
| TIAA | 459,061 | 0 | 0 | 0 | For |
| First Trust | 411,205 | 0 | 0 | 0 | For |
| Neuberger Berman | 350,745 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 347,272 | 0 | 0 | 0 | For |
| Goldman Sachs | 341,791 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 333,637 | 0 | 0 | 0 | For |
| ARK ETF Trust | 269,786 | 0 | 0 | 0 | For |
| MassMutual | 8,419 | 250,011 | 0 | 0 | Against |
Showing the 25 largest of 117 asset managers. All 117 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: To approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for purchase under such plan by 750,000 shares and remove the termination date of the plan.
Ionis Pharmaceuticals, Inc.’s own tally for this item (“4. Approve an amendment of the Amended and Restated 2000 Employee Stock Purchase Plan to increase the number of shares of common stock authorized for issuance under such plan by 750,000 shares and to remove the terminati”): 140,348,001 for, 332,204 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Ionis Pharmaceuticals, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 123 asset managers below reported 83,839,011 for, 1,765 against, 160 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,414,476 | 1 | 0 | 0 | For |
| Fidelity | 17,072,170 | 0 | 0 | 0 | For |
| Capital Group | 15,689,002 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,306,307 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 4,723,802 | 0 | 0 | 0 | For |
| BlackRock | 3,679,155 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 1,963,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,536,094 | 0 | 0 | 0 | For |
| State Street | 1,308,413 | 0 | 0 | 0 | For |
| JPMorgan | 1,296,917 | 0 | 0 | 0 | For |
| American Century | 1,275,849 | 0 | 0 | 0 | For |
| Jackson National | 982,760 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 800,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 598,636 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 594,587 | 0 | 0 | 0 | For |
| MFS | 573,889 | 0 | 0 | 0 | For |
| Invesco | 546,518 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 498,800 | 0 | 0 | 0 | For |
| TIAA | 459,061 | 0 | 0 | 0 | For |
| First Trust | 411,205 | 0 | 0 | 0 | For |
| Neuberger Berman | 350,745 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 347,272 | 0 | 0 | 0 | For |
| Goldman Sachs | 341,791 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 333,637 | 0 | 0 | 0 | For |
| ARK ETF Trust | 269,786 | 0 | 0 | 0 | For |
Showing the 25 largest of 123 asset managers. All 123 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
77% Approved · of votes cast
Description as filed by funds: To approve an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under such plan by 9,500,000 shares to an aggregate of 52,000,000 shares.
Ionis Pharmaceuticals, Inc.’s own tally for this item (“3. Approval of an amendment of the Amended and Restated Ionis Pharmaceuticals, Inc”): 108,377,084 for, 32,303,288 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 118 asset managers below reported 69,360,158 for, 13,792,761 against, 3,564 abstained, 160 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,414,372 | 105 | 0 | 0 | For |
| Fidelity | 3,494,139 | 13,578,031 | 0 | 0 | Mixed |
| Capital Group | 15,689,002 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,306,307 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 4,723,802 | 0 | 0 | 0 | For |
| BlackRock | 3,679,155 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 1,963,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,536,094 | 0 | 0 | 0 | For |
| State Street | 1,308,400 | 13 | 0 | 0 | For |
| JPMorgan | 1,296,917 | 0 | 0 | 0 | For |
| American Century | 1,275,849 | 0 | 0 | 0 | For |
| Jackson National | 982,760 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 800,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 598,636 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 594,587 | 0 | 0 | 0 | For |
| MFS | 573,889 | 0 | 0 | 0 | For |
| Invesco | 546,518 | 0 | 0 | 0 | For |
| TIAA | 459,061 | 0 | 0 | 0 | For |
| First Trust | 411,205 | 0 | 0 | 0 | For |
| Neuberger Berman | 350,745 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 347,272 | 0 | 0 | 0 | For |
| Goldman Sachs | 341,791 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 333,637 | 0 | 0 | 0 | For |
| ARK ETF Trust | 269,786 | 0 | 0 | 0 | For |
| MassMutual | 258,430 | 0 | 0 | 0 | For |
Showing the 25 largest of 118 asset managers. All 118 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
96% Approved · of votes cast
Prior year: 95.8% for (June 5, 2025 meeting) ▲ 0.5 pts
Description as filed by funds: To make an advisory vote on executive compensation.
Ionis Pharmaceuticals, Inc.’s own tally for this item (“2. An advisory vote on the compensation paid to the Company's executive officers, including the following resolution: "RESOLVED, that Ionis' stockholders approve, on an advisory (nonbinding) basis, the compensation of th”): 135,537,973 for, 5,088,105 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,414,466 | 11 | 0 | 0 | For |
| Fidelity | 17,072,170 | 0 | 0 | 0 | For |
| Capital Group | 15,689,002 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,306,307 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 4,723,802 | 0 | 0 | 0 | For |
| BlackRock | 3,679,155 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 1,963,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,536,094 | 0 | 0 | 0 | For |
| State Street | 1,308,413 | 0 | 0 | 0 | For |
| JPMorgan | 1,296,917 | 0 | 0 | 0 | For |
| American Century | 1,275,849 | 0 | 0 | 0 | For |
| Jackson National | 831,772 | 150,988 | 0 | 0 | Mixed |
| Franklin Custodian Funds | 800,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 598,636 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 594,587 | 0 | 0 | 0 | For |
| MFS | 573,889 | 0 | 0 | 0 | For |
| Invesco | 0 | 546,518 | 0 | 0 | Against |
| TIAA | 459,061 | 0 | 0 | 0 | For |
| First Trust | 411,205 | 0 | 0 | 0 | For |
| Neuberger Berman | 350,745 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 347,272 | 0 | 0 | 0 | For |
| Goldman Sachs | 341,791 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 333,637 | 0 | 0 | 0 | For |
| ARK ETF Trust | 269,786 | 0 | 0 | 0 | For |
| MassMutual | 258,430 | 0 | 0 | 0 | For |
Fund voting reports, all 115 managers: 82,444,220 for, 780,603 against, 1,764 abstained, 160 not voted, 216 mixed. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 24,401,303 | 165 | 0 | 0 | For |
| Capital Group | 21,161,984 | 0 | 0 | 0 | For |
| T. Rowe Price | 9,154,786 | 0 | 0 | 0 | For |
| Wellington | 5,622,981 | 0 | 0 | 0 | For |
| BlackRock | 4,399,050 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,980,754 | 0 | 0 | 0 | For |
| State Street | 3,181,029 | 3,841 | 0 | 0 | For |
| RBC Global Asset Management (U.S.) Inc. | 2,322,181 | 0 | 0 | 0 | For |
| Tweedy, Browne Co LLC | 2,158,924 | 0 | 0 | 0 | For |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1,979,669 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 1,748,458 | 0 | 0 | 0 | For |
| Artisan | 1,693,539 | 0 | 0 | 0 | For |
| Charles Schwab | 1,585,478 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 1,567,672 | 0 | 0 | 0 | For |
| Polar Capital Holdings Plc | 1,565,932 | 0 | 0 | 0 | For |
| American Century | 1,363,046 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,318,567 | 0 | 0 | 0 | For |
| Vanguard | 1,280,227 | 0 | 0 | 0 | For |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 1,096,374 | 0 | 0 | 0 | For |
| BNP Paribas Asset Management Holding S.A. | 0 | 867,805 | 0 | 0 | Against |
| Invesco | 0 | 858,410 | 0 | 0 | Against |
| UBS | 0 | 846,683 | 0 | 0 | Against |
| Northern Trust | 793,126 | 0 | 0 | 0 | For |
| GROUPAMA ASSET MANAGMENT | 743,355 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 730,020 | 0 | 0 | 0 | For |
Institutional-manager reports, all 398 managers: 107,403,087 for, 4,098,388 against, 7,444 abstained, 2,683 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
97% Approved · of votes cast
Prior year: 97.0% for (June 5, 2025 meeting) ▲ 0.3 pts
Description as filed by funds: To ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year.
Ionis Pharmaceuticals, Inc.’s own tally for this item (“5. Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2026 fiscal year”): 148,893,646 for, 4,000,539 against — passed, per its Form 8-K filed June 8, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved the foregoing proposal.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 117 asset managers below reported 83,278,949 for, 18,064 against, 1,764 abstained, 160 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 19,404,026 | 10,451 | 0 | 0 | For |
| Fidelity | 17,072,170 | 0 | 0 | 0 | For |
| Capital Group | 15,689,002 | 0 | 0 | 0 | For |
| T. Rowe Price | 5,306,307 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 4,723,802 | 0 | 0 | 0 | For |
| BlackRock | 3,679,155 | 0 | 0 | 0 | For |
| TWEEDY, BROWNE FUND INC. | 1,963,162 | 0 | 0 | 0 | For |
| Charles Schwab | 1,536,094 | 0 | 0 | 0 | For |
| State Street | 1,308,364 | 49 | 0 | 0 | For |
| JPMorgan | 1,296,917 | 0 | 0 | 0 | For |
| American Century | 1,275,849 | 0 | 0 | 0 | For |
| Jackson National | 982,760 | 0 | 0 | 0 | For |
| Franklin Custodian Funds | 800,000 | 0 | 0 | 0 | For |
| Waddell & Reed | 598,636 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 594,587 | 0 | 0 | 0 | For |
| MFS | 573,889 | 0 | 0 | 0 | For |
| Invesco | 546,518 | 0 | 0 | 0 | For |
| TIAA | 459,061 | 0 | 0 | 0 | For |
| First Trust | 411,205 | 0 | 0 | 0 | For |
| Neuberger Berman | 350,745 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 347,272 | 0 | 0 | 0 | For |
| Goldman Sachs | 341,791 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 333,637 | 0 | 0 | 0 | For |
| ARK ETF Trust | 269,786 | 0 | 0 | 0 | For |
| MassMutual | 258,430 | 0 | 0 | 0 | For |
Showing the 25 largest of 117 asset managers. All 117 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 165,262,556 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 11.75% |
| 2 | Fidelity | 10.33% |
| 3 | Capital Group | 9.49% |
| 4 | T. Rowe Price | 3.21% |
| 5 | NEW ECONOMY FUND | 2.86% |
| 6 | BlackRock | 2.23% |
| 7 | TWEEDY, BROWNE FUND INC. | 1.19% |
| 8 | Charles Schwab | 0.93% |
| 9 | State Street | 0.79% |
| 10 | JPMorgan | 0.78% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 14.77% |
| 2 | Capital Group | 12.81% |
| 3 | T. Rowe Price | 5.54% |
| 4 | Wellington | 3.40% |
| 5 | BlackRock | 2.66% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 2.41% |
| 7 | State Street | 1.93% |
| 8 | RBC Global Asset Management (U.S.) Inc. | 1.41% |
| 9 | Tweedy, Browne Co LLC | 1.31% |
| 10 | DEERFIELD MANAGEMENT COMPANY, L.P. | 1.20% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| FMR (Fidelity) | 24,556,637 | 14.86% | Form 13F, quarter ended March 31, 2026 |
| FMR LLC | 21,520,872 | 13.02% | Proxy statement (DEF 14A), proxy filed April 23, 2026 |
| Capital World Investors | 21,186,369 | 12.82% | Schedule 13G, filed May 14, 2026 |
| Vanguard Group | 16,440,459 | 9.95% | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 10,442,476 | 6.32% | Form 13F, quarter ended March 31, 2026 |
| Two Sigma | 5,857,629 | 3.54% | Form 13F, quarter ended March 31, 2026 |
| State Street | 3,995,564 | 2.42% | Form 13F, quarter ended March 31, 2026 |
| T. Rowe Price | 3,025,251 | 1.83% | Form 13F, quarter ended March 31, 2026 |
| JPMorgan Chase | 2,363,567 | 1.43% | Form 13F, quarter ended March 31, 2026 |
| Goldman Sachs | 1,699,847 | 1.03% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 165,262,556 shares outstanding, as reported by Ionis Pharmaceuticals, Inc. on its Form 10-Q dated April 23, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Ionis Pharmaceuticals, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 484 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 3,318 separate fund positions. On the most widely held item on that ballot — To make an advisory vote on executive compensation. — Ionis Pharmaceuticals, Inc.'s filing reports the proposal as approved, with 96% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Ionis Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 8, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Ionis Pharmaceuticals, Inc.’s 10-Q dated April 23, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Ionis Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Ionis Pharmaceuticals (IONS) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ionis-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.